Hospital

Investigators find that 1 45-minute session of moderate intensity exercise allows more exosomes to deliver the protein, ATP7A, directly to endothelial cells, which can help enable angiogenesis.

This combination improves patient outcomes of vaccine-induced thrombotic thrombocytopenia after a COVID-19 vaccination, according to the results of a case analysis.

Although COVID-19 paused our original plans, we were ultimately able to reach more people than we ever could have via in-person presentations alone.

Patient data are essential to providing coordinator care, but more data also creates heightened risks.

The Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) were previously granted priority review designation by the FDA for H. pylori infection.

Discovery has the potential to also benefit treatment choices, investigators from Georgetown Lombardi Comprehensive Cancer Center say.

Results of a meta-analysis of randomized clinical trials published in JAMA shows improvement in 6 of 8 domains.

For COVID-19 to turn into an endemic, there are a few criteria that must be met.

Legislation allowing pharmacists to prescribe contraceptives is becoming more widespread.

Cytisinicline demonstrated significantly better quit rates than placebo in 6 and 12 week trials.

Vosevi is a fixed-dose combination product containing sofosbuvir, velpatasvir, and voxilaprevir for the re-treatment of adults with chronic hepatitis C.

Tracy Russell, senior director of State Government Affairs at CoverMyMeds, discusses how the role of the pharmacist in the specialty pharmacy space has expanded during the COVID-19 pandemic.

Not only is burnout impacting pharmacists, but it also has unacceptable impacts on patients.

Tizlelizumab is a unique anti-PD-1 monoclonal antibody that is being analyzed in 14 pivotal clinical trials across an array of solid tumors.

Omidubicel is a first-in-class, advanced nicotinamide-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for individuals with blood cancers in need of a transplant.

Students from the University of the Sciences’ Philadelphia College of Pharmacy triumphed.

The advanced cell therapy is under development as an allogeneic hematopoietic stem cell transplant for patients with hematologic malignancies.

Most pharmacy schools don’t teach personal finance, so it’s up to you to set yourself up for success by taking control of your money while you’re still a student.

Nicole Palmer, senior manager of Volunteer Engagement at US Pharmacopeia (USP), and Michelle Then, PharmD, MBA, member of the USP Healthcare Safety and Quality Expert Committee, discuss the benefits of being a volunteer at USP and the opportunities for students and early career pharmacists.

Women in the study had higher rates of urgent procedures and were in poorer health when they received surgery.

How would you handle these patients' questions?

An overview for community pharmacies of a process to minimize vaccine errors using a COVID-19 vaccine point of distribution as an example.

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin designed to decrease contractile function and improve VO2 in patients with obstructive hypertrophic cardiomyopathy.

Voxelotor (Oxbryta) is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.

Data from the study shows a strong immune response in this age group following this dose, with no new safety signals.

Investigators observe strong immunogenicity profile in study participants aged 5 to 17 years 1 month after the primary vaccination series.

Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration.

Hogue is the second pharmacist to ever serve on the advisory committee.

Acute graft-versus-host disease (aGVHD) is the most frequently encountered, life- threatening complication following an allogeneic hematopoietic stem cell transplant (aHSCT).

Ravulizumab-cwvz (Ultomiris) is the first and only long-acting C5 complement inhibitor for the treatment of generalized myasthenia gravis to gain FDA approval.